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Abstract
Multiple myeloma (MM) is a malignancy of plasma cells that not only shows different
clinical behavior but also depicts heterogeneous groups at molecular level. The prognosis
of the disease has been dramatically changed with the arrival of new drugs in the past few
years. In this context of better therapeutic agents, there are important challenges for
accurate evaluation of patients by better prognostic and predictive tools. Transcriptomic
studies have largely added to decipher MM heterogeneity, dividing MM patients into
different subgroups according to prognosis. Micro-arrays and more recently RNA sequen-
cing have helped in evaluating coding and non-coding genes, mutations, unique trans-
criptome convertors and different splicing events giving new information concerning
biology, outcome and treatment options. Initial data from gene expression profiling stud-
ies have also pointed out genes that predict prognosis, i.e., CSK1-B, and can deliver phar-
macogenomics and biologic vision into the pathophysiology, targeted treatment, and
future direction. Importantly, we suggest that all prospective studies and clinical trials
now accept genetic testing and risk stratification of MM patients. In this review, we
discuss the part and effect of gene expression profiling in myeloma.
Keywords:multiple myeloma, monoclonal gammopathy of undetermined significance,
smoldering multiple myeloma, gene expression profile
1. Background
In literature, multiple myeloma accounts 1% of all malignancies and almost 10% of all hema-
tologic malignancies [1, 2]. Every year more than 20,000 new patients are diagnosed in the
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United States [3]. The age-adjusted annual incidence in the United States has lingered similar
for years at almost 4 per 100,000 [4]. Multiple myeloma is marginally more commonly reported
in men than in women, and is twofold as common in African-Americans as compared with
Caucasians [5]. At time of diagnosis of this disease, the median age is about 65 years [6].
2. Approach for diagnosis
The diagnosis of multiple myeloma requires the presence of one or more myeloma defining
events (MDE) in addition to evidence of either 10% or more clonal plasma cells on bone
marrow examination or a biopsy-proven plasmacytoma [7–12]. MDE consists of established
CRAB (hypercalcemia, renal failure, anemia, or lytic bone lesions) features as well as three
specific biomarkers: clonal bone marrow plasma cells ≥60%, serum free light chain (FLC) ratio
≥100 (provided involved FLC level is ≥100 mg/L), and more than one focal lesion on magnetic
resonance imaging (MRI). Each of the new biomarkers is associated with an approximately
80% risk of progression to symptomatic end-organ damage in two or more independent
studies. The updated criteria represent a paradigm shift since they allow early diagnosis and
initiation of therapy before end-organ damage [13–16]. The rate of progression is influenced by
the underlying cytogenetic type of disease; patients with t(4;14) translocation, del(17p), and
gain(1q) are at a higher risk of progression from SMM to multiple myeloma [17–19].
When multiple myeloma is suspected clinically, patients should be tested for the presence of
M proteins using a combination of tests that should include a serum protein electrophoresis
(SPEP), serum immunofixation (SIFE), and the serum free light chain (FLC) assay [20]. App-
roximately 2% of patients with multiple myeloma have true non-secretory disease and have no
evidence of an M protein on any of the above studies [6]. Bone marrow studies at the time of
initial diagnosis should include fluorescent in situ hybridization (FISH) probes designed to
detect t(11;14), t(4;14), t(14;16), t(6;14), t(14;20), trisomies, and del(17p) [21]. Conventional
karyotyping to detect hypodiploidy and deletion 13 has value, but if FISH studies are done,
additional value in initial risk-stratification is limited. Gene expression profiling (GEP) if
available can provide additional prognostic value [22].
3. Molecular classification
Although multiple myeloma is still thought to be a single disease, it is in reality comprises of
collection of variable cytogenetically distinct plasma cell malignancies [23–30]. On fluorescent
in situ hybridization (FISH) studies of the bone marrow, approximately 40% of multiple
myeloma cells have trisomies (trisomic multiple myeloma), while remaining have transloca-
tion involving the immunoglobulin heavy chain (IgH) locus present on chromosome 14q32
(IgH translocated multiple myeloma) [31–34]. In small subset of patients both trisomies and
IgH translocations are found simultaneously. Trisomies and IgH translocations are primary
cytogenetic abnormalities and observed at the time of establishment of MGUS. In addition,
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secondary cytogenetic abnormalities developed during the disease course of multiple mye-
loma, including gain(1q), del(1p), del(17p), del [13], RAS mutations, and secondary transloca-
tions of MYC. Both primary and secondary cytogenetic abnormalities can influence disease
progression, response to treatment, and overall prognosis [30].
4. Prognostication
The median survival of this disease is approximately 6–7 years; especially ASCT (Autologous
stem cell transplant) eligible patients 4 year survival rates exceed 80%. However, behavior
ofmalignancies is unpredictable, prognosis depends on patient characteristics such as age,
co-morbids as well as disease characteristics such as disease stage, biology (cytogenetic abnor-
malities), and response to therapy [35, 36] Stage, i.e., tumor burden in multiple myeloma, is
being evaluated by using the Durie-Salmon Staging (DSS) and the International Staging
System (ISS) [37–39]. Disease biology best assessed by molecular abnormalities of multiple
myeloma and the presence or absence of secondary cytogenetic abnormalities such as del(17p),
gain(1q), or del(1p) [21, 29]. In literature, it is emphasized that the interpretation and impact of
cytogenetic abnormalities are different according to the disease phase [30]. The recent staging
system, Revised International Staging System (RISS) combines stage and disease biology
(presence of high risk cytogenetic abnormalities or elevated lactate dehydrogenase level) to
better define not only prognosis but guide treatment options [40].
It is important to note that in order to ensure constant availability, only three widely available
cytogenetic markers are used in the RISS. Patients with standard risk multiple myeloma have a
median overall survival (OS) of >7 years while those with high risk disease have a median OS of
approximately 3 years despite tandem autologous stem cell transplantation (ASCT) [41, 42]. In
addition to cytogenetic risk factors, two other markers that are related with rapid disease pro-
gression are elevated serum lactate dehydrogenase and plasma leukemic cells in circulation [43].
5. Pathways involved in multiple myeloma
5.1. PI3K/MEK/ERK pathways in myeloma
The phosphatidylinositol 3-kinases (PI3Ks) are a group of intracellular enzymes that phos-
phorylate the 3-OH group at the inositol ring of phosphatidylinositol leads to activation of
PI3K/AKT signaling pathway that is responsible for chemoresistance [44]. PI3K signaling is
inhibited by Phosphatase and tensin homolog (PTEN) and activated by insulin like growth
factor 1 (IGF-1) and interleukin-6 (IL-6) But there is no FDA approved PI3K inhibitors for MM
[44]. Inhibition of this pathway alone is not showing meaningful clinical responses in studies.
MEK/ERK pathway is co-functioning with the PI3K/AKT [45]. Both pathways decrease apo-
ptosis [45]. Resistance to treatment develops secondary to cross talk between pathways [45].
Therefore, targeting both pathways together may be an effective therapeutic strategy and has
been proved in certain cancers, i.e., in melanoma and renal cell carcinoma [45].
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5.2. Ras/MAPK pathway in myeloma
Ras protein family (H, K and N-Ras) send downstream signals that attracts growth-factor-
receptor bound protein 2 (Grp2) and sons of Seven less (SOS) [46]. The grp2/SOS combination
then converts Ras to active form by changing GTP to GdP [46]. Activated Ras recruits Raf to the
cell membrane by phosphorylation [46]. This process is antagonized by GTPase-activating pro-
teins, which promote GTP hydrolysis and the formation of inactive Ras-GDP complexes [46].
Mitogen-activated protein kinases (MAPKs) are a family of expressed kinases that convey cell
surface signals into the cell. MAPK pathways are activated via a phosphorylation cascade [47].
The most proximal kinase in these pathways, the MAPK kinase kinase (MAPKKK or MAP3k),
engaged by extracellular signals, phosphorylates a dual specificity MAPK kinase (MAPKK or
MAP2K), which in turn phosphorylates and actives the distil effector MAPK [47].
The Ras/MAPK pathway consists of the Ras proteins, a family of small G-coupled molecules, the
Raf kinases (MAP3K), the MAP2K kinases (MEK1 and MEK2) and ERK1 and ERK2 [47]. The
Ras/MAPK network is frequently deregulated in malignancy and causes uncontrolled cellular
proliferation and resistance to drug [47]. MEK is present at a junction of the Ras/MAPK pathway
[47]. Amplification of Ras/MAPK pathway leads to the aggressive tumor characteristics [45]. In
MM, certain translocation points the overall prognosis. The t(4;14) translocation overexpresses
fibroblast growth factor receptor 3 overexpression that activates the Ras/MAPK pathway that
subsequently leads to decreased apoptosis [45]. Incidence of activating Ras mutations is between
32 and 50% in MM (K-Ras and N-Ras), are also deregulate this pathway [46]. Novel agent
RO5126766 showed activity in RAS- and RAF-mutated malignancies (lung and gynecological
cancers) [48]. It also showed partial response in myeloma patient in Maxime Chenard-Poirier
study [48].
5.3. Bruton’s tyrosine kinase (BTK)
Bruton’s tyrosine kinase (BTK) belongs to Tec family of tyrosine kinases [49]. The Tec family
comprises of BTK, BMX, ITK, TEC, and RLK. BTK is the most commonly studied member of
the Tec family and is present in different stages of B cells [49]. But this protein is absent in T
lymphocytes and normal plasma cells [50]. On B cells and myeloma cells BTK controls signal
pathways including PI3K, PLCγ, and PKC in multiple myeloma [49]. These pathways play
important functions in cell propagation, expansion, delineation and survival [49]. BTK attract
MM cells toward stromal cell-derived factor-1 (SDF-1) which is present at high levels in the BM
[49]. BTK expression is correlated with SDF-1 receptor CXCR4 in myeloma cells [51]. BTK
inhibition leads to the inhibition of anti-apoptotic proteins Bcl-xL, survivin and FLIPL and
stimulates caspase-controlled apoptotic death within the myeloma cells [52]. One of the BTK
inhibitor, ibrutinib, inhibits MM cell growth, osteoclasts or mesenchymal stem cells growth
in vitro [53]. As a single agent, BTK inhibitor CC-292 did not show anti-myeloma activity
in vitro but reveals negative impact on osteoclasts function. Interestingly, high levels of BTK
have been reported as a poor prognostic marker in MM patients [52]. Therefore, we need
targeting agents against this protein (BTK) to not only control microenvironment but also
malignant plasma cells [54].
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5.4. HSP70
Pathways, like HSP70, ubiquitin-proteasome and unfolded protein response (UPR) and auto-
phagy pathways help neoplastic cells to adjust according to stress that is produced by immu-
noglobulin overload in the endoplasmic reticulum (ER) [55]. Heat shock protein 70 is one of
the pathways that increase survival of myeloma cells by inhibiting gh APAF-1 and caspase 9
[55]. HSP expression is activated by heat and other stressors, i.e., radiation and chemotherapy
exposure [56]. HSP70 family comprises of 13 proteins. Proteins of this family are: HSPA1A and
HSPA1B (called together as HSP70 or HSP72), HSPA5 (BIP), HSPA8 (HSC70), and HSPA9 [55].
Hsp proteins consist of an N-terminal ATPase domain, a C-terminal domain, and a middle
portion. After binding of ATP, Hsp undergoes a conformational change [57]. The middle
segment is binding site for protein kinase PKB/Akt and is implicated as the main site for client
protein interactions [58].
Recent studies reveal that tumor cells with high levels of HSP70 have beneficial effect of
proteasome inhibitors [55]. This protein represents a possible target to establish a new approach
for multiple myeloma treatment [55]. HSF1 knockdown sensitizes myeloma cells to bortezomib
treatment [55]. Bustany et al. study strongly suggests that HSF1(HSP) inhibitors might be
promising agents in combination with bortezomib-based therapeutic protocols to treat MM
patients with adverse prognosis or in relapse [59]. Bustany et al. study, strongly suggest that
HSF1(HSP) inhibitors might be promising agents in combination with bortezomib-based thera-
peutic protocols to treat MM patients with adverse prognosis or in relapse [60].
5.5. MicroRNAs (miRNAs)
MicroRNAs (miRNAs) are a group of 18–24 nucleotides, non-coding RNA molecules. Mature
one attaches to 30’UTR non translated site and control gene expression by translation modifi-
cation or mRNA degradation [61]. They have substantial impact on post-transcriptional nega-
tive regulation of oncogenes (e.g. MYC, MDM2) and tumor suppressor genes (e.g. TP53,
PTEN) [62]. miR-145 is tumor suppressor miRNA in MM, miR-145 mimics inhibited p-AKT
and p-PI3K, impairing proliferation and survival of MM cells [63]. Until now, around 700
miRNAs have been revealed in humans. Each miRNA can target at least 200 genes [64].
Anderson et al. identified a MM-specific miRNAs print that is evident by degradation of
miRNAs -15a/-16 and over expression of miRNAs -222/-221/-382/-181a/-181b [64]. They also
reported that these miRNAs control proliferation and growth of MM cells by inhibiting AKT
serine/threonine protein-kinase (AKT3), ribosomal-protein-S6, MAP-kinases, and NF-_B-acti-
vator MAP3KIP3. Furthermore these miRNAs exerted their activity even on bone marrow
microenvironment [64]. One of the poor prognostic cytogenetics in myeloma is deletion of
chromosome 13 that has been associated with overexpression, of miRNA-17_92 cluster
(located on chromosome 13) in these patients [80]. In another study, miRNA-15 and -16, were
down-regulated in MM patients having ch13 deletion [63].
The miRNA analysis showed contrary relationship between five assumed target genes
(RAD54L, CCNA2, CYSLTR2, RASGRF2 and HKDC1) [61]. Anti-MM effects are also linked
with miR-137 and miR-197. Studies showed that miR-34 and miR-125a inhibitors upregulates
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p53 related miR-192 and -194 and inhibits oncogenesis and migration while enhance apoptosis
[63]. miR-202 is down-regulated in bone marrow microenvironment and treatment with miR-
202 mimics to inhibit growth by decreasing BCL-2 and BAFF levels [63].
5.6. Histone
Histone acetyl transferase (HAT) and histone deacetylase (HDAC) are enzymes that regulate
expression of genes by moving acetyl from acetyl-CoA to the lysine residue of histones [65].
Subsequently, hyper acetylated histones aggravate transcription [65]. HDACs are enzymes
that catalyze the removal of acetyl groups from amino lysines in histones, resulting in relaxa-
tion of the DNA around the histones and suppression of transcription [66]. HDACs are
divided into five groups: class I (HDAC1, HDAC2, HDAC3, and HDAC8), class IIa (HDAC4,
HDAC5, HDAC7, and HDAC9), class IIb (HDAC6 and HDAC10), class III (SIRT family), and
class IV (HDAC11) [66]. Inhibiting HDAC converts histones in hyperacetylation form and
leads to alter gene expression [67]. In malignant cells, many HDAC inhibitors (HDACi) have
shown good anti-tumor activities with anti-proliferative, pro-apoptotic and anti-angiogenic
properties [67]. SAHA (suberoylanilide hydroxamic acid) is one of the HDACi, showed
antimyeloma activity by inhibiting proteasome and expression of its subunits, and increases
myeloma cell sensitivity to Bortezomib [68]. Extrinsic and intrinsic apoptotic pathways, non-
apoptotic cell death, i.e., autophagy pathways and cytokines and proteins implicated in mul-
tiple myeloma survival, progression and immune escape have been documented in myeloma
cells treated with an HDACi [67]. The cellular pathways controlled by SAHA include IGFIGF-
1RAkt, IL-6gp130 and proliferative/antiapoptotic factors (e.g., NF-B, XBP-1, and E2F-1) [68].
Myeloma cells have overexpression of antiapoptotic proteins Bcl2 and Mcl1 and down regula-
tion of pro-apoptotic protein Bax [67]. These findings depict resistance to chemotherapeutic
agents [67]. Treatment with depsipeptide in myeloma cell line resulted in a decrease of the anti-
apoptotic proteins Mcl1, Bcl2, BclxL and an increase in Bax [67]. 5-azacitidine is a DNA
methyltransferase inhibitor shows activity against myeloma [67]. Azacitidine and analogs such
decitabine are interesting agents to investigate hypermethylation in tumorigenesis and the
clinical efficacy is under investigation in phase II trials [67]. In S. B. Khan s study, depsipeptide
(HDACi) induces apoptosis in MM cells and shows an additive effect with melphalan [65].
5.7. Microenvironment
Microenvironment is defined as surrounding cells and tissues can impact the growth of specific
cells by changing the pH, oxygen levels, nutrients, and antiapoptotic factors [69]. when this
microenvironment is dysfunctional leads to disease progression, particularly in cancer. Like in
other parts of body, the bonemarrow has ownmicroenvironment [69]. That is classically defined
as to have two niches: the endosteal (osteoblastic) niche and the vascular (sinusoidal) architec-
ture [69]. The osteoblastic niche comprises of reticular cells, fibroblasts, and adipocytes [70]. They
provide supportive matrix for stem cells [70]. The vascular niche has important functions in bone
marrow: transfer oxygen, nutrients and growth factors to hematopoietic cells for proliferation
and differentiation of cells; support of homing and recruitment through chemokines [70].
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The BM milieu of MM consists of extracellular matrix, hematopoietic and nonhematopoietic
cells along with cytokines, growth factors, and adhesion molecules [70]. The increased osteo-
clastic activity is secondary to increase cytokines, i.e., IL-6, IL-1b, tumor necrosis factor (TNF)-α,
and parathyroid hormone-related protein [70]. Other causes of osteoclast activation are: Mye-
loma cells express RANKL, TNF-α, and inactivation of RANKL decoy receptor and OPG. The
destroyed bone environment stimulates platelets to release TGF-β and IGF-I that will cause
myeloma genesis [70]. Not only osteoclast is activated, osteoblasts are also inhibited in myeloma.
Factors responsible for inhibiting osteoblast are TGF-β and IL-3 [70]. Extracellular matrix of the
myeloma show increased expression of angiogenic factors and their receptors, i.e., vascular
endothelial growth factor (VEGF) and VEGF receptor-2, fibroblast growth factor-2 (FGF-2) and
FGF-2 receptor-2, platelet-derived growth factor receptor beta (PDGFR-β) and ECs-released
VEGF and IL-8 [70]. In the bone microenvironment, myeloma cell are surrounded by immune
competent cells [68]. Because of certain growth factors rapid expansion of immature myeloid
cells which fail to differentiate and, impede immune system and leads to oncogenesis [68].
Specific CD8+ T cells has been recognized in microenvironment, inhibiting CD4 + cell growth
by releasing interferon gamma causing immunosuppression [68]. The T-cell activity is also
suppressed by the activation of PD-1 receptor with its ligand [69].
The PI3K-Akt signaling has been demonstrated to phosphorylate HKII Hexokinase II to acti-
vate Glycolytic pathway in MM cells [69].
A number of intracellular signaling pathways, i.e., NF-κB, Akt, p38MAPK, protein p62, Pim-2
are over-in both MM cells and their BM microenvironment [69]. Pim kinases are also involved
in drug resistance by activating drug efflux transporters [69]. Pim-1 phosphorylates the ATP-
binding cassette (ABC) transporter ABCG2 that subsequently causes drug resistance [69]. The
side population (SP) phenotype is a feature of stem cells in tissues. The SP cells are associated
with the expression of genes involved in the glycolytic pathway including GLUT1, GLUT3,
and PDK1 and the glycolysis appears to be highly accelerated in SP cells [69]. The inhibition of
glycolysis via targeting these SP cells can disrupt the drug resistance [69].
Immune microenvironment consists of T Cells, NK and NKT Cells, dendritic cells, myeloid
derived suppressor cells and adipocytes [70]. Reciprocal increase in IL-17, IL-17 induces mye-
loma tumor cell growth and inhibits immune function in myeloma patients [70]. Impaired
differentiation and function of NK and NKT cells have been recognized in MM. A major
contributing factor to this immune dysfunction is believed to be IL-6 mediated [70]. Myeloid-
derived suppressor cells (MDSCs) expands during cancer, inflammation and infection and
have ability to suppress T-cell responses (Table 1) [71]. Recently, it has been proposed that a
5-fold increase in MDSCs in newly diagnosed MM [70] Tables 1–3.
5.8. Marrow-infiltrating lymphocytes
Lymphocytes residing in the bone marrow are called marrow infiltrating lymphocytes [72].
These MILs need to be activated and expanded in vitro to destroy malignant cells. Difference
between peripherally derived T lymphocytes and marrow derived lymphocytes is: MILs have
a ability to recognize a wide variety of proteins on the surface of the tumor cells than do cells
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that obtained from the blood [73]. So on relapse after receiving CAR T cells therapy, new type of
antigen or protein are developed on tumor cell surface (similar to the antibiotic resistance) [73].
While MILs can identify a huge variety of proteins on tumor cells, problem of resistance is
significantly lower [73].
Growth factors/cytokines Possible mechanism of actions
PTH, VIT D3, IL-1, IL-11 Activates osteoblast and stromal cells
PD-1 on T cells PD-L1 on myeloma cells
VEGF, IL-6 on stromal cells Raf/MEK/ERK activation on myeloma cells
VEGF, TGF-β, FGF from stromal cells Angiogenesis
G-CSF and IL-6 induced a higher level of phospho-STAT3 in neutrophils Angiogenesis
IL-10 Plasma cell proliferation and angiogenesis
Wnt, Dickkopf Wnt signaling pathway 1 (DKK1), fibroblast growth factor
(FGF)
Decreased increased osteoblast number
Decreased bone mineral density
Downregulating expression of the RANK-L decoy receptor (OPG)




Abbreviations: PTH, parathyroid hormone; VIT D3, Vitamin D3; IL-1, IL-11:Interleukin1/11; VEGF, vascular endothelial
growth factor receptor; TGF-β, transforming growth factor beta; FGF, fibroblast growth factor; G-CSF, granulocyte colony
stimulating factor; RANK-L, receptor activator of nuclear factor kappa beta.Source: Mondello et al. [71].
Table 1. Bone marrow micro-environment.
















Drug resistance (Cytokine mediated)
*van de Donk et al. [80].
**Kizaki and Tabayashi [81].
Table 2. Intracellular signaling pathways in the pathogenesis of multiple myeloma.
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Adoptive T-cell therapy (ACT) has been assessed in trials, in which activated tumor-specific
T cells has been used to activate antitumor immunity after myeloablative chemotherapy in
patients with multiple myeloma (MM) [73]. But efficacy of this approach is limited by the
tumor-non specific T cells [73]. In phase I study, Noonan and colleagues assess the safety, and
efficacy of this approach in 25 patients in multiple myeloma patients [74]. MILs infused after
autologous stem cell transplant in 22 patients and found complete remission/partial response/
stable disease in six/seven/five patients [74]. Progression-free survival was correlated
with greater than 90% reduction in tumor burden (25.1 vs. 11.8 months) [74]. Borrello




Inhibitor of microRNA genes EZH2
inhibitor
Preclinical studies
Irreversibly inhibition of 20S proteasome, pan-
proteasome inhibitor
Marizomib Phase 1 clinical trials, relapsed/refractory. Trials
ongoing for CNS involvement in myeloma
Oral 26S proteasome inhibitor Oprozomib Phase 1 studies relapsed/refractory
Anti-CD138 monoclonal antibody conjugated to
DM4, inhibitor of the microtubule assembly
Indatuximab Phase 1/2 clinical trials, relapsed/refractory
Monoclonal antibody to CD38 SAR
(SAR650984)
Phase 1 clinical trials, relapsed/refractory
Histone deacetylase (HDAC) 6 inhibitor Panobinostat Phase 3 clinical trials
HDAC6-specific histone deacetylase inhibitor Ricolinostat Preclinical studies
Non-specific histone deacetylase inhibitor Vorinostat Phase 3 clinical trials
Alkylating agent Bendamustine Phase 1/2 trial PR rate of 52%, with very good PR
achieved in 24%
AKT kinase inhibitor Afuresertib
(PKB115125)
Phase 1 studies ORR—50% in relapsed/refractory
Bcl-2 inhibitors ABT 199 Preclinical studies
BTK inhibitors Ibrutinib Phase 2 dose escalation study, relapsed or
refractory
Inhibitor of cyclin-dependent kinases (CDKs) Dinaciclib Phase 2 dose escalation study
IL-6 inhibitors Siltuximab Phase 2, newly diagnosed MM, VGPR rate was
significantly improved but not CR rate
Kinesin spindle protein (KSP) Filanesib
(ARRY-520)
Phase 2 clinical trials, ORR was 58%, relapsed/
refractory




Heat-shock protein 90 inhibitor Tanespimycin Phase 1 dose-escalation study
Source: Refs. [139, 140].
Table 3. Potential Target for Multiple Myeloma.
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antitumor immunity [73]. Results from small studies are encouraging but need confirmation in
a larger trials [73].
5.9. PD-1/PD-L1
The PD-1 receptor is present on T, B cells, monocytes, and natural killer (NK) T cells when
activated to certain antigen stimulus [75]. PD-L1 and PD-L2 are present on antigen presenting
cells, i.e., dendritic cells and macrophages [75]. After contact of PD-1 to PD-L1 or PD-L2, this
complex reduces secretion of Th1 cytokines, inhibits T-cell proliferation and inhibits CTL-
mediated killing [75]. In the physiologic state, this pathway maintains immunologic equilib-
rium. While, in pathologic settings, e.g., in malignancy, over expression of this pathway leads
to to activation and function of cancer related T-cell populations, which supports for immune
escape and tumor proliferation [75]. PD-L1 expression is also documented in cells of the tumor
microenvironment, i.e., myeloid-derived suppressor cells that helps in escape to natural body
defense system [75]. To improve already decrease immunity in myeloma patients, strategies
have been explored at molecular and cellular levels [76]. These are: passive immunotherapy
with monoclonal antibodies that hit myeloma specific antigens; cancer vaccines; T-cell therapy
and change immunosuppressive microenvironment of the bone marrow via immunomodula-
tory medicines or by inhibiting immune checkpoints [76]. There are studies under process for
PD-1 receptor/PD-L1 and PD-L2 inhibitors in myeloma, i.e., Pembrolizumab in combination
with IMiDs [77]. Preliminary results of a phase II trial with pembrolizumab with pomali-
domide showed 50% objective response with near complete and very good partial responses
in refractory patients [77].
5.10. Monoclonal antibodies
In 2015, two monoclonal antibodies were approved for the treatment of relapsed or refractory
multiple myeloma (RRMM), elotuzumab and daratumumab [78]. CD38 is a type II cell mem-
brane glycoprotein. It has multiple functions in cell to cell adhesion, enzymatic (cellular nucleic
acid metabolism) activity [77]. It is present on a multiple hematopoietic and non-hematopoietic
cell types. Cell that harbors this receptor are: medullary thymocytes, activated B and T lym-
phocytes, NK cells and dendritic cells [77].
Daratumumab is a fully humanized monoclonal IgG-κ antibody directed that works against
CD38 of myeloma cells [77]. It exerts its effects like other monoclonal antibodies, i.e., antibody
dependent cytotoxicity, complement mediated cytotoxicity and antibody dependent phagocy-
tosis (ADCP), induction of autophagy/apoptosis [77].
Antibodies targeting CD38 are easily tolerated and showed partial response or better in
approximately 30% of relapsed/refractory MM patients as single agent [79]. In future, deep
responses and better progression-free survival can be obtained by combining them with
immunomodulatory agent or proteasome inhibitors [79].
In phase I/II study recently published by Lokhorst et al., impressive clinical responses were
seen in heavily pretreated patient population with 64% double refractory to PIs and IMiDs and
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had undergone ASCT in 76% [77]. Daratumumab as a single agent yielded 36% overall
response rate in 16 mg/kg arm and remarkably, in the responder group, 65% remained pro-
gression free in 12 months [77].
Elotuzumab is a monoclonal IgG-κ antibody works against signaling lymphocytic activation
molecule F7 (l surface receptor helps in activation of natural killer cell) [78]. This antibody
induces cell death via antibody dependent cytotoxicity (ADCC) and inhibits CS1-mediated
MM cell adhesion to bone marrow stem cells [79].
In phase III ELOQUENT-2 study, different regimens with this agent were tried in relapsed/
refractory setting. It was found that 1-year PFS rate was higher in the ELO-LEN-DEX (-
Elotuzumab-Lenalidomide-Dexamethasone) arm (68 vs. 57%), and this difference was slightly
greater at 2 years (41 vs. 27%). Other targeted antigens on which trials are being conducted are:
CD74, CD138, B-cell activating factor, interleukin-6 [79].
5.11. CARTcells
CART cells, is made by fusing the variable fragment (scFv) of a monoclonal antibody (mAb)
with intracellular signaling domain related to CD-19 related antigen [77]. The MHC-
independency, in vivo expansion and memory cell growth make these cells more beneficial
the antibodies [77]. Plasma cells do not have a strong CD-19 expression but Garfall et al. have
observed a relatively more frequent expression than previously reported [77]. In 43 years old
patients after nine lines of treatment this approach showed remission. This generates a hypoth-
esis that there may be a role of this strategy even in minimally/weakly expressed antigens
Currently, it remains unclear whether concurrent targeting of multiple antigens (such as CD38,
CS1, BCMA, CD138, etc.) is helpful for achieving eradication of myeloma clone [77]. For CART
cells, costimulatory molecules are required to prevent the immune system from eradication of
these cells, but best costimulatory antigen is not known yet. Few costimulators are under
study, these are: CD19, CD138, CD38, CD56, Lewis Y, CD44v6, CS1, and BCMA.
In new data from a Garfall pilot study, after anti-CD19 CAR and a salvage SCT, progression-free
survival (PFS) was reported after first-line SCT in 3 of 10 study participants. In 2017, studies
with chimeric antigen receptor (CAR)-T cells targeting B-cell maturation antigen (BCMA) have
shown good response in relapsed/refractory myeloma patients. But this option is impeded by
short half lived effector cells, acute toxicity, and host immune responses against CARs.
6. Pathways involved in multiple myeloma
6.1. Gene expression profile (GEP) and molecular variability in myeloma
The MM transcriptome has been evaluated in different groups [81–84]. Different genes have
been explored between MM and normal plasma cells and also during different phases of
disease. Impaired control of certain genes of the Cyclin D family (CCND1, CCND2 and
CCND3) appeared to be a universal characteristic of MM cells, especially early MGUS
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(monoclonal gammopathy of undetermined significance) stage [43]. The mechanisms elaborate
in Cyclin D mutation are multiple and comprised of 1—cyclin D amplifications, 2—transloca-
tion of CCND1 or CCND3 with the IgH gene in the t(11;14) and the t(6;14), 3—trisomies and
other cytogenetics events that incidentally contribute to over-expression of CCND genes. In
particular, CCND2 is overexpressed in certain group of patients that carry t(4;14) and t(14;16)
MM [81, 82]. These observations allowed classification of MM in eight subgroups in the
translocation cyclin D (TC) classification [43]. Additional studies have observed other molecu-
lar subgroups independent of Cyclin D involvement and linked with other clinical and pheno-
typical characteristics. For example, a Low-Bone subgroup, that includes MM patients with
minimal or few bony lesions and minimal expression of Dickkopf WNT Signaling Pathway
Inhibitor 1 (DKK1) or the proliferative subgroup which shows over expression of specific cell
cycle- and proliferation-associated genes [83]. Overall, GEP emphasis an important molecular
heterogeneity in this disease. Over 500 genes have a substantial difference between the differ-
ent clinical subgroups [43]. Cytogenetic changes, mainly hyperdiploidy and translocations
involving IgH are highly connected with certain molecular subcategories clusters. For exam-
ple, t(4;14) which primes to the over-expression of the histone methyl transferase Multiple
Myeloma SET Domain (MMSET) is linked with a specific gene expression profile secondary
to MMSET activity [85]. More globally, HDMM and NHDMM can be observed by using
GEP [86].
6.2. Definition of myeloma pathogenesis by using GEP
In order to explore the molecular basis of myeloma cell development, several studies have
observed GEP at the different stages of the disease [87]. In these studies, normal plasma cell
was compared with cells during different stages of MM i.e. MGUS cell, Myeloma, smoldering
MM, newly-diagnosed symptomatic MM, relapsed MM and cells from patients with plasma
cell leukemia (PCL) by using GEP [87]. In one study of 877 patients, authors concluded that
MGUS plasma cells share similar features with MM and relapse MM but have different genes
and pathways that are expressed lately during MM progression [87]. These activated pathways
comprises of E2F activation, cMYC and chromosomal instability genes and these demonstrates
a possibility of progression to MM if exist at MGUS or SMM stage [88]. Other groups have
examined other different genes, i.e., antiapoptotic DNA repair, NF-kB and cytokines-signaling
pathway related genes in established MM cells in comparison with premalignant MGUS cells
[88]. Interestingly, influence of microenvironment on gene profile of the MM cells has been
assessed that confirmed activation of crucial critical pathways such as Notch and Ras, NF-kB,
and genes affecting proliferation, survival, cell cycle regulators/activation in MM cells [89].
6.3. Link of prognosis with GEP
Ability to explore complete transcriptomic expression profile of MM cell provided an unique
opportunity to confirm predictive role of GEP on disease behavior. Clinical trials and long
term follow-up of MM patients revealed the ability of GEP to predict prognosis in different
cohorts. Many studies have identified gene expression signatures capable of predicting EFS
and OS in MM by using different approaches. Most of these studies have shown GEP profile as
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an independent prognostic factor. Some studies have used a biological approach with respect
to specific features of MM cells. Chromosome instability signature [90], centrosome index
signature, and cell death profile [91] were explained based on instability of genomes, whereas
a 7-gene prognostic expression profile was developed from MM cell lines study [92, 93]. Other
prognostic signatures like the 15-gene prognostic signature or the proliferation signature have
also been published in literature [94]. Other groups evaluated GEP signature correlation
between GEP with overall survival of MM patients in separate cohorts. The HOVON-
65/GMMG-HD4 clinical trial researchers [94], the Intergroup Francophone du Myeloma 99
clinical trial [84], and UAMS researchers [95] published reports on 92, 15 and 70 genes signa-
ture respectively [95]. Importantly, only minimal or no genes overlay between these signatures
signifying that each signature does not encompass all high risk patients and also highpoints
the dismissal in the system. In an attempt to streamline GEP use in clinical practice and to
define a distinctive tool, amalgamation of existing prognostic signatures have been recently
reported. That combination will define a single reliable signature that might be able to predict
outcome in MM at diagnosis and relapse [96].
Interestingly, GEP signature has also shown significance in early stages of MM or in plasma
cell leukemia patients. Investigators from UAMS have reported that 70-genes signature and its
derivative are able to predict outcome in context of MGUS and SMM [97]. In the context of
PCL, in a cohort of 21 patients, a 27 gene expression signature was identified as an indepen-
dent prognostic factor [24].
6.4. Transcriptome modifiers profiling
The RNA-sequencing have been created and will be incorporated into GEP to enhance estima-
tion of the outcome in the future [98]. Of these modifiers, non-coding RNA are mainly
researched in MM since reports have already proved that micro-RNA contribute to myeloma
formation and can be used to predict prognosis or response to auto-transplant [98]. MiR17 and
miR886-5p have been observed as a strong prognostic indicator in a study of 163 newly
diagnosed patients from the MRC Myeloma IX l trial [99]. Recent literature is now signifying
importance of microRNAs MM and separate MM subgroups [100]. For example, miR-126
stimulates cMYC overexpression in t(4;14) MM [101], and miRs-192, -194, and -215 leads to
impaired control of p53 and MDM2 in a subgroup of MM, causing poorer outcome [102, 103].
Very interestingly, overexpression of circulating microRNAs, which are easily access for inves-
tigations has been researched and may represent a decent prognostic biomarkers in MM [104].
Furthermore, management options that can reestablish miRNAs (Tumor suppressor miRNA)
or impede miRNAs (Oncogene miRNA) are in process to be used as major therapeutic option
in the future [105, 106]. Long noncoding RNAs (lnc RNA) are also being sensibly studied
inMM. Samur et al. with others is currently identifying important changes in deregulation of
lncRNAs over- or underexpression and its impact on clinical outcome [108].
In post-transcriptional event, alternate splicing is an important event that extremely increases
the transcript collection affecting number of cell development process including cell growth
and survival. It has been documented as important marker of malignant phenotype and the
knowing the alternate splicing events will help in future to better predict prognosis in MM.
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There is evidence that splicing events affect specific genes as hyaluronan synthase 1 (HAS1)
[109] or deleted in colorectal carcinoma gene (DCC) occur repeatedly in MM [110], or that a
targeted therapy that control the splicing of X-box binding protein 1 (XBP1) increases sensitiv-
ity of MM cells to proteasome inhibitor. Pilot investigations by Nagoshi et al. as well as and by
some other researchers have identified important number of spliced isoforms in myeloma in
comparison to normal plasma cells with regards to both functional concern as well as prog-
nostic importance. Interestingly, the ability to depict mutations at the RNA level is becoming
well recognized entity. DNA-based studies in MM, including mainly whole exome sequencing,
have emphasized the mutational background of the disease, which includes few repeated
mutations (NRAS, KRAS, TP53, DIS3, and FAM46C). NFkB and ERK trails are the most
involved pathways, with mutations in 43 and 17% of MM cases respectively [111–114].
Although only specific mutations have a clear impact on prognosis (TP53, ATR, and ATM)
until now. The capability to diagnose these mutations at the RNA level [114] can now be used
to predict outcome that can be integrated in the future models expecting prognosis in MM.
Finally, next generation sequencing helps us to perform single cell studies. This method,
exemplified by the drop-seq technology [115], allows documentation of the variable clones as
well as identification of the transcriptome in the reference of the microenvironment. The initial
data regarding single cell transcriptome assessment depicts exciting applications [116] includ-
ing amalgamation into a new GEP signature [117].
6.5. GEP and variability in clones
Intraclonal variability is an important characteristic of cancer that has been shown in MM
[118, 119]. It refers to malignant cells having same genomic changes but with subtle differences
in mutations, copy number abnormalities and chromosome changes including translocations
among different clones. In MM cells, the evaluation of Ig gene rearrangement by next-
generation sequencing is particularly helpful. Munshi NC et al. did deep sequencing of the
IgH gene at time of diagnosis and relapse in a large series of patients emphasizing the
complexity of the clonal and sub-clonal architecture of the disease [120]. However, only few
reports have been published the evolution of in MM. Four patterns of this clonal changes have
been observed [112, 121]. The modification in sub clonal copiousness will be correlated with
changes in GEP. For example a linear development may not meaningfully influence on overall
GEP, on the other hand branching evolution may reveal decrease in expression of genes
representing clones The ability to assess transcriptome at a single cell level might be essential
in order to define the true influence of intraclonal heterogeneity on GEP and to recognize
potential marker of sensitivity or resistance to specific therapeutic drugs [116, 122].
6.6. Significance of GEP in combination with ISS
A recent study reported GEP in combination with clinical prognostic marker in MM compris-
ing cytogenetic alterations and ISS score. This study used different GEP signature and revealed
that the combination of GEP with ISS is a useful and better prognostic tool that significantly
improves risk stratification then alone ISS [123]. Recognizing high risk patients remains an
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important task to try and modify treatment in future discussed by Landgren and Rajkumar in
this CCR Focus section [124]. Currently, no specific targeted agent therapy is indicated espe-
cially for the high-risk patients in upfront setting, there is increasing emphasis on including
multi-agent therapy as consolidation followed by transplant and post-transplant maintenance
in transplant eligible patients. High dose melphalan followed by autologous stem cell trans-
plant (ASCT) appears to be the best consolidation therapy to date in multiple studies [125].
6.7. Response to treatment prediction by using GEP
GEP has also been assessed to forecast complete response (CR) to different treatment as well.
CR is an independent factor to not only tell progression free survival but also an indirect
marker of overall survival [126]. A precise GEP signature has been identified with reference
to upfront three drug combinations (VTD) in newly diagnosed MM, high dose therapy (54
IMiDs/dexamethasone, tandem auto-transplant at relapse and the bortezomib-based regimen
[129]. However, a prediction model research that compared different dataset has shown that
GEP alone is not well-organized to predict CR in different datasets [127–130].
In this study, various methods have been used to develop a response predictive model; even
with the best GEP-based CR predictive model, precision was between 56 and 78% that was
found in different datasets. The ability to predict CR was not affected by different methods
used measure GEP, or treatment regimens used or in newly-diagnosed or at time of relapsed
patients. This study signifies the fact that it may be necessary to combine multiple other
genomic parameters in response predicting model in future.
6.8. Personalized therapy assortment
Based on GEP, the derangements in certain pathways can be controlled and offer an important
information to guide treatment therapy. For example, the presence of high DKK1 level, that
shows bone involvement can be explored for the use of anti-DKK1 drug [131, 132] or the
assessment of the ratio between BCL2/MCL1 level can point out the sensitivity to BH3 mimetic
drugs [133]. On the other side, combining the information of gene expression with mutation
expression helps to select treatment options as personalized medicine [134]. The detection of
precise mutations such as BRAF V600E can direct for use of BRAF inhibitor such as
vemurafenib [135, 136], or mutations triggering the MAPK pathway can give us rationale for
the use of MEK inhibitors such as trametinib [137]. Other targetable mutations such as SF3B1,
FGFR3, ATM/ATR, IDH1/2, and CCND1 as well as RAS/RAF, NFkB pathway-linked genes
have been described in myeloma. These mutations can be controlled by appropriate inhibitors.
Some mutations can also be assessed to predict drug sensitivity. Initial data of one study,
revealed that the presence of NRAS mutations in relapsed cases is associated with inferior
response to bortezomib [138] or in contrast, that the occurrence of IRF4 mutations is related
with higher sensitivity to immuno-modulatory agents [111]. These data needs confirmation in
further clinical trials but it is hypothesis generating study.
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The documentation of specific micro-RNA expression profile can also be exploited to guide
therapy. Several microRNAs are being researched as treatment targets with hopes for devel-
opment of small molecules that target these micro-RNA function.
Similarly, GEP has been employed to predict resistance to antimyeloma drugs with an inter-
pretation that harmful agents are avoided that are not helpful. With the help of number of
B-cell lines including multiple myeloma cell lines, a microarray-based GEP signature was
established to predict resistance of melphalan. Although the expression profile was able to
predict sensitivity vs. resistance in cell lines, its practical application needs further studies to be
done [102, 103]. Interestingly, a pharmacogenomic study of global GEP of myeloma cells
recovered from myeloma patients and specific time after administration of different drugs
have been assessed [104, 105]. Prognostic information was acquired from GEP of refined
plasma cells 2 days after providing thalidomide and dexamethasone or bortezomib to newly-
diagnosed myeloma patients. An 80-gene signature was recognized following bortezomib
administration that will guide us in future for better patients’ risk stratification [105].
From treatment as well as prognostic points, it is also important to consider persistent changes
in genome which occurs without stimulus or as well as under the influence of microenviron-
ment, epigenomic changes or therapy. Therefore, assessment by GEP at a single time point
may not be meaningful. The advancement of GEP from diagnosis, response and relapse should
be interpreted intelligently to have an answer for proper selection of the most appropriate
therapy.
7. Potential target for multiple myeloma
7.1. Constraint of GEP in existing clinical practice
Important impediments still present to prevent application of this important investigation in
general clinical practice. Although many specific GEP signatures have been recognized and a
recent study has joint some of these signatures to create a unique signature [32] but no
consensus have been accepted to date for universal use for every MM patients. GEP remains
a research tool and is not yet authenticated by the FDA. For clinician point of view, the GEP
data have been created generally in a setting of certain treatments that includes thalidomide,
lenalidomide and bortezomibwith or without auto-transplant. Since the therapeutic landscape is
largely progressing inMM, re-assessments are required for each novel drug and/or combination.
In particular the arrival of new therapeutic classes such as antibody drug conjugates, targeted
agents (Elotuzumab, Daratumumab) and new IMiDs and proteasome inhibitors [106, 107] mark-
edly improve the prognosis and may need different GEP studies and signatures [107, 114]. GEP
has been utilized to date in few myeloma centers and mostly for investigational purposes. The
development of investigators friendly and quicker methods should be considered. Simple quan-
titative PCR has been assessed in a group of 157 newly diagnosed patients proved good accept-
able results [115]. However, a final conclusion about this test is still pending. Most importantly
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an integrated approach that includes gene signatures, mutational profile and microRNA expres-
sion will be requisite to allow a wider application of genomic information to direct for treatment
selection as well as prognostication. Taking the current understanding of these landscape genetic
assessment to the next level, it will be essential to understand the clinical influence of clonal
content and advancement along with identification of sub-clonal variants and molecular alter-
ations on disease outcome [141]. The current information about mutational load that predicts
outcome will need to be re-investigated for treatment purpose. These algorithms will be
amended with the arrival of immunotherapeutic strategies which may have great achievement
in malignancies with high mutational load. Again, as demonstrated by Rashid NU et al.
with other colleagues Mutations must be studies further as predictive markers for treatment
decisions [97].
8. Future trend
There is tremendous progress has reported so far, newer high-throughput technologies are
being added with clinical parameters [142]. Array-based methodologies, sequencing-based
method, and newer bio-informatics methodologies are in process of development. Further-
more, integrative oncogenomic work are merging new markers such as mutations, splicing
events, noncoding RNA, miRs with older ones to help in better prognostication [143]. The
personalized medicine depends on the assortment of a targeted therapy guided by the specific
mutation or GEP signature is attractive tool treatment option. However, in future, in MM
patients, treatment option selection depends on coexistence of sub-clones, dynamic evolution
of the disease and triggering mutations in pathway, i.e., KRAS and BRAF for the ERK path-
ways [144].
To conclude, gene expression profile studies provide important knowledge regarding MM
pathogenesis, and establish a powerful tool for prediction of outcome and to direct clinicians
for selection of therapy [145]. The grouping of mutational profile, gene expression and splicing
events with ISS and cytogenetic may become a standard of care in MM care [97].
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